Print   |  A  |  A
Board Directors

The Board of Directors are responsible for creation of the strategic planning of the organisation, the Corporate Governance and the management of the Chief Executive Officer.

The Board Chairperson is Professor Andrew Scott who has had a significant experience in the management and strategic direction of CTA.

The other members of the Board serve on many government committees involved in health stratgeies for cancer patient management and engage in strategic development with many major global drug development groups. This provides CTA with a mix of skills essential for an organisation acting as a service provider in the field of Cancer Clinical Trial Management.

Chairman: Prof Andrew Scott

FAANMS, FAICD, MD, DDU, FRACP, ECFMG, MB BS (Hons), Bachelor of Medicine and Bachelor of Surgery (with Honours)

Andrew currently holds the positions of Scientific Director of PET, Department of Molecular Imaging and Therapy, Austin Health, and Laboratory Head at the Olivia Newton-John Cancer Research Institute. He is one of Australia’s top clinician/scientists with great experience in both preclinical and clinical drug development. In addition, he is on the Board of many significant organisations including the Australian Nuclear Science and Technology Organisation (ANSTO), World Federation of Nuclear Medicine and Biology, of which he is the current President, and Chair of the International Relations Committee, Australian and New Zealand Society of Nuclear Medicine (ANZSNM). He is also a Fellow of the Australian Institute of Company Directors.

Andrew has published over 260 peer reviewed papers and 20 book chapters, principally in the areas of oncology and molecular imaging. Invited reviews in leading journals include Nature Reviews Cancer and Cancer Research. He is actively involved in the training and mentoring of young scientists and clinicians and currently supervises several doctoral students in addition to post-doctoral fellows and Nuclear Medicine trainees.

Andrew is the current CTA Chairperson


Dr Julian Clark

Dr Julian Clark is currently Head of Business Development at the Walter and Eliza Hall Institute in Melbourne and for several years has operated his own consulting business, Julian Clark Consulting Pty Ltd. Drawing on more than 25 years of international and cross-cultural business experience in growing and leading technology and healthcare enterprises, large and small, Julian assists organizations with development, commercialization and organizational strategies to secure sustainable growth.

Dr Clark has many years direct experience in developing and commercializing pharmaceuticals, biotechnologies, laboratory instrumentation and industrial processes and consumer products. His broad international experience has been gained through senior positions in Pharmacia, Biochrom and others in Sweden, Great Britain, Japan, North America, India and Australia. In recent years he has been particularly active in translating business opportunities across the public-private interface.

Dr Clark was also the founding CEO of the Cancer Therapeutics CRC and is a Fellow of the Australian Academy of Technological Sciences and Engineering, and a Member of the Australian Institute of Company Directors. He has a PhD from the University of Glasgow and an Honorary Doctorate from the University of South Australia. Currently, Julian is a Director of Alchemia Limited and Cancer Trials Australia, Chair of the Advisory Board, Sansom Institute, University of South Australia; and an Associate of the Centre for R&D Leadership, University of Melbourne.

Dr Julian Clark is a member of the Finance & Audit Subcommittee

Dr Peter Briggs

Dr Peter Briggs

Medical Oncologist


Monash Health

Dr Peter Briggs has broad experience in Medical Oncology and Clinical Haematology, with particular interests in lung cancer, breast cancer and haematoncology.

Dr Briggs is Head of the Medical Oncology department at Southern Health. He has a long clinical career in general clinical oncology in private & public practice. Over recent years he has focused particularly on lung cancer management and clinical research in this field. In addition to his duties at the Monash Cancer Centre, Dr Briggs conducts a private medical oncology practice at Moorabbin Specialist Centre.


Mr Colin Nugent B Com,CA (SA), ACA

Colin joined the CTA Board in June 2015.

Colin is a current member of the Aust & NZ Inst of Chartered Accountants and owns a consulting practice offering strategic and financial services to the healthcare sector.

Colin is a “Big 4” trained Chartered Accountant, graduated from the University of Cape Town and gaining his CA (SA) membership. He obtained his Australian ACA accreditation in 1983.

Colin has extensive commercial and technical experience across a broad range of national and global companies. The last 25 years have been spent in the Healthcare space with companies such as Ipsen, Kendle (now INC Research ) , Medisence (Abbott Labs), holding Fin. Dir and Brd positions in these and other organisations.



Prof David Ashley

Professor Ashley has had an extensive research career in cancer clinical care and research over two decades.  He has in excess of 130 peer reviewed publications and numerous reviews, abstracts and invited scientific presentations across a variety of domains including laboratory based Cancer Research, clinical trials, public health and Psycho-Oncology research. In recent years his focus has been in particular neurologic tumours and the epigenetics of cancer.
His achievements in research have led to change in practice in the care of children and adults with malignancies including the introduction of new standards of practice for the delivery of systemic chemotherapy. 
Professor Ashley is highly regarded for his work as evidence by numerous invitations to plenary sessions and symposia of international standing.  He has been the principal investigator of number of national and international studies.

Ms Michelle Gallaher

Michelle Gallaher is the Creative Director of The Social Science. Healthcare and biotechnology are her fields of expertise having worked in biotech start-ups, major teaching hospitals, research organisations and pharmaceutical companies throughout her 20+ year career.  As former CEO of the BioMelbourne Network, the peak body for biotech and med-tech in Melbourne,  Michelle developed a contact network that spans far more than Melbourne’s innovations sector, reaching as far as Beijing, Manchester, San Diego and Boston. Michelle is a recognised super tweeter in the international biotech space, recently listed as a top 20 tweeter at BIO 2013 and holding the number 1 spot on the BIO top tweets list. She has a passion for Twitter, Instagram, LinkedIn and Pinterest and is a regular blogger on a number of local and international biotech and med-tech sites. - See more at:


Professor John Seymour

Professor John Seymour

Director: Cancer Medicine; Director: Department of Haematology


Peter MacCallum Cancer Centre

Professor Seymour is the Director of Cancer Medicine at Peter Mac and a member of many scientific committees including the Victorian Government Consultative Council on Human Research Ethics, Scientific Advisory Committees for the International Workshop on NHL, International Conference on Malignant Lymphoma, and Board of Directors of the International Extranodal Lymphoma Study Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group and is a frequently invited speaker nationally and internationally. He is the Editor-in-Chief of Leukemia and Lymphoma and on the editorial boards of the Journal of Clinical Oncology, British Journal of Haematology, and Leukemia Research. He has also authored 13 book chapters, more than 300 peer-reviewed publications (which have been cited more than 8,000 times), and 500 conference abstracts. Heavily committed to clinical and translational research, Professor Seymour is national study chairman for 12 ongoing national or international clinical trials.


CEO, Cancer Trials Australia
Dr Kurt Lackovic

Dr Lackovic commenced as CEO of Cancer Trials Australia in January 2017.

Kurt has a PhD in chemistry and a post-doctorate in medical genetics (University of Umeå, Sweden). He is a Graduate of the Australian Institute of Company Directors, and a member of the Licensing Executives Society of Australia and New Zealand, Ausbiotech and the NHMRC Research Translation Faculty.

Kurt has extensive experience in leading complex academic and clinical programs, strong connections to Industry, and strategic linkages to senior executives in Government and major teaching Hospitals. He has worked in early stage drug discovery with a focus on oncology targets, management of WEHI’s High Throughput Screening Facility, led multiple Cancer Therapeutics CRC projects involving national and international partners, and has overseen day-to-day management of the Melbourne Genomics Health Alliance. 

Back to Top